Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients

References

• Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2004;48:4680–4686.
   PubMed Web of Science ®Google Scholar
• Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol. 2005;79:12773–12782.
   PubMed Web of Science ®Google Scholar
• Intelence – European Medicines Agency – Europa. Available online at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000900/WC500034180.pdf. Accessed 15 September 2015.
   Google Scholar
• Katlama C, Clotet B, Mills A, et al. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther. 2010;15:1045–1052.
   PubMed Web of Science ®Google Scholar
• Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS. 2009;23:2289–2300.
   PubMed Web of Science ®Google Scholar
• Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:29–38.
   PubMed Web of Science ®Google Scholar
• Pugliese P, Cuzin L, Cabie A, et al. A large French prospective cohort of HIV-infected patients: the Nadis Cohort. HIV Med. 2009;10:504–511.
   PubMed Web of Science ®Google Scholar
• Gupta SK. Intention-to-treat concept: a review. Perspect Clin Res. 2011;2:109–112.
   PubMedGoogle Scholar
• Fatkenheuer G, Duvivier C, Rieger A, et al. Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial. J Antimicrob Chemother. 2012;67:685–690.
   PubMed Web of Science ®Google Scholar
• Nguyen A, Calmy A, Delhumeau C, et al. A randomized crossover study to compare efavirenz and etravirine treatment. AIDS. 2011;25:57–63.
   PubMed Web of Science ®Google Scholar
• Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005;143:714–721.
   PubMed Web of Science ®Google Scholar
• Fumaz CR, Munoz-Moreno JA, Molto J, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr. 2005;38:560–565.
   PubMed Web of Science ®Google Scholar
• Shubber Z, Calmy A, Andrieux-Meyer I, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS. 2013;27:1403–1412.
   PubMed Web of Science ®Google Scholar
• Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. 2001;15:1261–1268.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35:182–189.
   PubMed Web of Science ®Google Scholar
• Casado JL, Mena A, Banon S, et al. Efficacy and safety of etravirine-containing regimens in a large cohort of HIV/HCV coinfected patients according to liver fibrosis. J Int AIDS Soc. 2014;17(4 Suppl 3):19574.
   PubMedGoogle Scholar
• Lopez-Cortes LF, Viciana P, Giron-Gonzalez JA, et al. Clinical and virological efficacy of etravirine plus two active Nucleos(t)ide analogs in an heterogeneous HIV-infected population. PLoS One. 2014;9:e97262.
   PubMed Web of Science ®Google Scholar
• Vingerhoets J, Calvez V, Flandre P, et al. Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data. HIV Med. 2015;16:297–306.
   PubMed Web of Science ®Google Scholar
• Fagard C, Colin C, Charpentier C, et al. Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial. J Acquir Immune Defic Syndr. 2012;59:489–493.
   PubMed Web of Science ®Google Scholar
• Gazzola L, Cicconi P, Ripamonti D, et al. Efficacy and safety of darunavir/ritonavir plus etravirine dual regimen in antiretroviral therapy-experienced patients: a multicenter clinical experience. HIV Clin Trials. 2014;15:140–150.
   PubMed Web of Science ®Google Scholar
• Ruxrungtham K, Pedro RJ, Latiff GH, et al. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naive, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. HIV Med. 2008;9:883–896.
   PubMed Web of Science ®Google Scholar
• Martins AN, Arruda MB, Aleixo AW, et al. Prevalence of etravirine-associated mutations in clinical samples with genotypic resistance to nevirapine and efavirenz in Brazilian clinics. J Acquir Immune Defic Syndr. 2011;57(Suppl 3):S193–S196.
   PubMed Web of Science ®Google Scholar
• Gallien S, Charreau I, Nere ML, et al. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine. J Antimicrob Chemother. 2015;70:562–565.
   PubMed Web of Science ®Google Scholar
• Poveda E, Anta L, Blanco JL, et al. Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database. AIDS. 2010;24:469–471.
   PubMed Web of Science ®Google Scholar
• Calin R, Paris L, Simon A, et al. Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy. Antivir Ther. 2012;17:1601–1604.
   PubMed Web of Science ®Google Scholar